What’s up everyone and a very happy belated thanksgiving for all those
who celebrated it. We have recently seen Longeveron blow up from a penny stock
by 1000% in the last 5days which is phenomenal.
And this is on the back of Longeveron recently announcing that the FDA granted a Rare Pediatric
Disease designation to their experimental drug which treats a rare heart defect.
What’s up everyone, so in this video I share with you updates on two top penny stocks which we have
covered before - AQST and Dare Biosciences, which analysts rate a strong buy and have
significant upside potential. These penny stocks have FDA approval dates planned for December,
so the clock is ticking for them to take off pending any successful approval.
And if you watch till the end, I have another new gem to share with you,
which analysts are equally very bullish about and one to watch as we get into 2022.
So please don’t forget to drop a quick like on the video and
turn on the notification bell to get these big runners instantly.
We mostly cover OTC stocks on the channel as the right gems have significant upside potential and
one of the most frequently asked questions on the channel is what is a good platform to
buy OTC stocks from. So please permit share with you this exciting platform Colmex Pro
which I recently came across and they are also sponsors of this video, after we established that
they have a decent platform and rewards scheme which could benefit some of the viewers of the
channel. So in summary if you’re interested in trading in OTC penny stocks above 1cent,
then this is for you as they have a unique product and sophisticated platform.
The platform also offers CFDs and Forex but the current focus here is on equities.
Setting up an account with Colmex could take between 1 hour to 24 hours,
which means as clients you can start trading the same days as you open the account.
And the average execution time is one of the fastest meaning, if you are day trading
or a swing trader, you would find this really useful with lots of benefits as they have lots
of functionalities to suit your day trading needs. As a client you would have a personal
account manager assigned to yourself to provide you with full support also including technical
support. They have a minimum deposit of $500 and have a black Friday deal ending on the
29th November where you get a free stock once you make a deposit within certain thresholds..
They also have stellar reviews on Trust Pilot which gives a view on what other users think
of the platform. They are a fully regulated EU broker and are registered with regulators as
well as professional and governmental bodies. And so essentially they provide a cross-border
regulatory environment for investment firms active within the European Economic Area. So if this is
of interest to you please check out the link to Colmex Pro in the top pinned comment to see what
the platform has to offer and get trading OTC stocks if you don’t already do. Thank you lots.
With that said, let’s jump straight into it with our first banger on the day which is
Acquestive Therapeutics Inc (Nasdaq: AQST) first called here on the channel in August at $3.62
and it has bounced very well and now sitting at $6.24 with a market cap of $251m. It is up 33%
in the last month and 82% in the last 6months but as we know AQST has some
save the dates in December which could leave these price levels in its shadows.
AQSR Reported Third Quarter 2021 Financial Results, Providing Business Updates and Improved
their Full Year Guidance. They highlighted that their Libervant™ Buccal Film continues
to progress through the FDA review process in advance of PDUFA goal date of December 23, 2021.
AQST-109 top line Phase 1 trial demonstrated positive clinical results comparable to
autoinjectors for the emergency treatment of allergic reactions, including anaphylaxis
Their CEO, Keith Kendall, commented that they continue to interact with the FDA regarding the
NDA submission for Libervant, including responding to several information requests to date. They are
continuing to prepare for commercialization with payer and sales force planning underway.
They recently demonstrated clinical results comparable to the autoinjectors in the recently
completed Phase 1 trial for AQST-109, potentially the first orally administered epinephrine product
for the emergency treatment of allergic reactions, including anaphylaxis.
Before year end, they anticipate receiving written feedback from the FDA following their
pre-IND meeting request and plan to commence an adaptive design crossover study that will
determine the final formulation and dose strength leading to their pivotal PK study in 2022.
The Company believes that Libervant, if approved by the U.S. FDA for U.S. market access,
will enable a larger share of patients to receive more appropriate treatment by providing consistent
therapeutic dosing in a non-invasive and innovative treatment form for epileptic seizures.
AQST is developing Libervant as an alternative to more invasive, inconvenient, and difficult
to administer device driven products, including a rectal gel and nasal spray,
for patients with refractory epilepsy. A large portion of the patient population
still does not access either one of these existing products and remains underserved.
So AQST continues to actively engage with the FDA regarding its accepted
New Drug Application for Libervant ahead of the Prescription Drug User Fee Act target goal date
of December 23, 2021. So clearly a date to save in your diaries if you hold this stock.
In their third Quarter 2021 Financials, they reported that total revenues were $13.3
million in the third quarter 2021, compared to $8.3 million in the third quarter 2020.
For the third quarter 2021 compared to the prior year period, the Company saw an 18%
increase in Sympazan net revenue and a 77% increase in manufacture and supply revenue.
In terms of outlook, they said Sympazan and the Company's other on-going business activities
generated strong operating results during the first half of 2021. As a result, the Company
has revised its full year revenue expectations to between $47 to $49m up from between $46 to $48m
AQST has 4 analysts covering the stock & all with a strong buy rating.
And the analysts mid price targets of $17.50 gives it an upside of 196% and if you want to
be even more bullish you are looking over 350% upside to a $28 per share price target on this
gem over the next 12 months which is an incredible upside. Again this targets have lots of risks and
assumptions and rely on everything falling to place, but yet still an exciting outlook.
Next up to our number 2 penny stock which is Dare Bioscience (DARE) called at $1.51
and it is now sitting at $1.74 with market cap of $132mn. Its share price is up 20% on
the month and in the last 6 months it is also 38% having also had multiple highs and lows recently.
Daré Bioscience Reported Third Quarter 2021 Financial Results and Provided a Company
Update. They reported significant progress on several key clinical and corporate initiatives
with their portfolio during the third quarter, including DARE-BV1 NDA acceptance
and Ovaprene NIH CRADA for the pivotal Phase 3.
They were also actively advancing clinical development and strategic partnerships to
maximize value of pipeline candidates. The FDA accepted their NDA for DARE-BV1
for priority review with a PDUFA target date of December 7, 2021, and they entered into a CRADA
under which a pivotal Phase 3 clinical study of Ovaprene® will be supported by the NICHD’s
Contraceptive Development Program and conducted within its Contraceptive Clinical Trial Network.
They also initiated a Phase 1/2 clinical study of DARE-VVA1, their intravaginal tamoxifen program.
The Key Portfolio Objectives for 4Q 2021 included PDUFA target action date for the NDA
of December 7, 2021 for DARE-BV1: Announcement of U.S. commercialization strategy
and Robust market introduction in the 1st Half of 2022, if approved.
They also ended the period of September 30, 2021 with $45.6 million in Cash and cash equivalents,
compared to $4.7 million at December 31, 2020. They also had a comprehensive loss
of approximately $12.7 million, as compared to $7.6 million for 3Q 2020.
Dare has 2 analysts covering the stock, all with moderate buy ratings. The analysts mid price
target of $4 per share gives it an upside of over 133%, over the next 12months. So again, whichever
way you look at it, analysts are very bullish on the potential and outcome of the FDA submission
due by the end of the year aswell with an upper price target of $5 per share.
So December could be a period of explosion for these two penny stocks.
Next up to our number 3 gem stock for your watchlist is Oramed Pharmaceuticals,
Inc (ORMP) which has blown up from a penny stock earlier this year and is sitting nicely at $18.58
per share market cap of $604mn. Oramed has had a fantastic year so far being up 64%
in the last 6m and 321% ytd and looking at its area of focus and its market cap,
it appears it still has a long way to go. It has taken a big dip recently from its highs of $28
per share which it hit earlier in November which provides good buy the dip opportunities.
Oramed Pharmaceuticals has developed an innovative technology to transform
injectable treatments into oral therapies. Their flagship product, an oral insulin capsule,
has the potential to better the lives of millions of diabetics around the world – allowing,
type 2 patients to begin insulin therapy earlier without fear of needles. Oramed’s oral insulin
is currently in advanced clinical trials under the US FDA for both type 1 and type 2 diabetes.
Oramed Reached 75% Enrollment in Phase 3 Oral Insulin Study.
They announced that they had enrolled and randomized over 75% of the 675 patients
planned for their Phase 3 ORA-D study of their oral insulin capsule for the treatment of type
2 diabetes (T2D). And their CEO Nadav Kidron said they were excited to announce that they
were nearing the end of enrollment in the world’s first Phase 3 oral insulin study
conducted under the FDA protocols and they anticipate announcing topline results in 2022.
So really exciting stuff. So if you think about far this stock has evolved prior FDA approval,
then the outlook would be explosive should their trial be successful
and it gives an indication of how far the other two stocks could go.
Oramed Shares also rose 18% After Inclusion to the MSCI USA Small Cap Index. Their common
stock will be added to the Index effective Tuesday, November 30th at the close of market
and inclusion of their stock in a growing number of indexes can expand their shareholder base.
Oramed has 3 analysts covering the stock and all with a strong buy rating.
And the analysts mid price targets of $35 per share gives it a decent upside of 91.5%
and if you want to be even more bullish you are looking $40 per share
which is over 100% from current price levels. So equally exciting times ahead.
So some very very interesting and mindblowing prospects ahead for these stocks
but only consider getting in if the price is right for you and if you fully understand the
risks. This video is not financial advice, a buy or a sell recommendation, but is meant to
bring some new and exciting stocks to your attention for you to do your own research..
As always I would love to hear from you, so please let me know your thoughts on these
top stocks in the comments section below and what other penny stocks are catching your eyes lately.
And If you are new to my channel, please ensure to subscribe and hit the bell so you are notified
when I upload new videos. If you would like to see more videos like this, please check out this
video right here or this playlist right here to watch equally insightful content from the channel.
Thank you so much for being here and I look forward to have you in my next video. Thank you